SCYNEXIS (0L49) Price & Analysis

Compare

0 Followers

0L49 Stock Chart & Stats

$0.78

-$0.07(-5.38%)

At close: Jan 08 4:00 PM EST

$0.78

-$0.07(-5.38%)

Day’s Range― - ―

52-Week Range$0.66 - $1.47

Previous CloseN/A

Volume178.00

Average Volume (3M)9.15K

Market Cap

$32.28M

Enterprise Value-$8.96M

Total Cash (Recent Filing)$44.78M

Total Debt (Recent Filing)$2.39M

Price to Earnings (P/E)―

Beta1.70

Next Earnings

Nov 05, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding41,924,942

10 Day Avg. Volume8,353

30 Day Avg. Volume9,146

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.28

Enterprise Value/Revenue-2.75

Enterprise Value/Gross Profit-4.73

Enterprise Value/Ebitda0.31

Forecast

1Y Price Target

$4.00

Price Target Upside412.82% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial PositionThe resolution with GSK strengthens the financial position of Scynexis by securing a $22M payment and extending its cash runway to over 2 years.

Market DemandThe global rise in fungal infections creates a growing need for next-generation antifungals like SCY-247.

Product DevelopmentThe focus remains on advancing SCY-247, a next-generation antifungal, following positive Phase 1 data in healthy subjects.

Bears Say

SCYNEXIS News

Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study

SCYNEXIS (SCYX) announced that it will receive a $22 million payment from GlaxoSmithKline Intellectual Property as part of...

12d ago

SCYX

Scynexis announces results from Phase 1 SAD/MAD study of SCY-247

SCYNEXIS (SCYX) announced results from a Phase 1 study of SCY-247, its second-generation triterpenoid antifungal under development for...

27d ago

SCYX

SCYNEXIS: Strategic Advancements and Financial Stability Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SCYNEXIS. The associated price target remains...

11d ago

SCYX

SCYNEXIS and GSK Amend License Agreement

SCYNEXIS ( ($SCYX) ) has shared an update. On October 14, 2025, SCYNEXIS and GSK signed a binding...

12d ago

SCYX

Buy Rating on SCYNEXIS: Promising Potential of SCY-247 Amid Market Volatility

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on SCYNEXIS, with a...

26d ago

SCYX

Promising Potential of SCY-247: A Game-Changer in Antifungal Treatment

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SCYNEXIS. The associated price target remains...

2M ago

SCYX

Scynexis announces presentations highlighting data on SCY-247

SCYNEXIS (SCYX) announced multiple upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the...

2M ago

SCYX

Optimistic Outlook on SCYNEXIS: Strategic Developments and Financial Health Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on SCYNEXIS, retaining the price target of $4.00....

2M ago

SCYX

SCYNEXIS Reports Improved Financials Amidst Strategic Developments

SCYNEXIS Inc ( ($SCYX) ) has released its Q2 earnings. Here is a breakdown of the information SCYNEXIS...

2M ago

SCYX

Scynexis reports Q2 EPS (14c), consensus (19c)

Reports Q2 revenue $1.36M, consensus $154,000. “We are excited about the continued progress of our second-generation fungerp candidate,...

3M ago

SCYX

SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment

SCYNEXIS Inc (($SCYX)) announced an update on their ongoing clinical study. Study Overview: SCYNEXIS Inc. is conducting a...

3M ago

SCYX

SCYNEXIS Inc. Advances Antifungal Treatment with Phase 3 Study

SCYNEXIS Inc (($SCYX)) announced an update on their ongoing clinical study. Study Overview: SCYNEXIS Inc. is conducting a...

3M ago

SCYX

SCYNEXIS Holds Annual Meeting, Re-elects Directors

SCYNEXIS ( ($SCYX) ) just unveiled an update. On June 25, 2025, SCYNEXIS, Inc. conducted its Annual Meeting...

4M ago

SCYX

SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price

The latest announcement is out from SCYNEXIS ( ($SCYX) ). On June 20, 2025, SCYNEXIS received a notification...

4M ago

SCYX

0L49 FAQ

What was SCYNEXIS Inc’s price range in the past 12 months?

SCYNEXIS Inc lowest share price was $0.66 and its highest was $1.47 in the past 12 months.

What is SCYNEXIS Inc’s market cap?

SCYNEXIS Inc’s market cap is $32.28M.

When is SCYNEXIS Inc’s upcoming earnings report date?

SCYNEXIS Inc’s upcoming earnings report date is Nov 05, 2025 which is in 9 days.

How were SCYNEXIS Inc’s earnings last quarter?

SCYNEXIS Inc released its earnings results on Aug 13, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.05.

Is SCYNEXIS Inc overvalued?

According to Wall Street analysts SCYNEXIS Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SCYNEXIS Inc pay dividends?

SCYNEXIS Inc does not currently pay dividends.

What is SCYNEXIS Inc’s EPS estimate?

SCYNEXIS Inc’s EPS estimate is -0.22.

How many shares outstanding does SCYNEXIS Inc have?

SCYNEXIS Inc has 41,924,942 shares outstanding.

What happened to SCYNEXIS Inc’s price movement after its last earnings report?

SCYNEXIS Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -2.959%.

Which hedge fund is a major shareholder of SCYNEXIS Inc?

Currently, no hedge funds are holding shares in GB:0L49

SCYNEXIS Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.22%

Trailing 12-Months

Asset Growth

-43.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS (0L49) Earnings & Revenues

Historic Earnings Reports

0L49 Stock 12 Month Forecast

Average Price Target

$4.00

▲(412.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.8,1.0461538461538462,1.2923076923076924,1.5384615384615385,1.7846153846153847,2.0307692307692307,2.276923076923077,2.523076923076923,2.769230769230769,3.0153846153846153,3.2615384615384615,3.5076923076923077,3.753846153846154,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.8,1.0461538461538462,1.2923076923076924,1.5384615384615385,1.7846153846153847,2.0307692307692307,2.276923076923077,2.523076923076923,2.769230769230769,3.0153846153846153,3.2615384615384615,3.5076923076923077,3.753846153846154,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.8,1.0461538461538462,1.2923076923076924,1.5384615384615385,1.7846153846153847,2.0307692307692307,2.276923076923077,2.523076923076923,2.769230769230769,3.0153846153846153,3.2615384615384615,3.5076923076923077,3.753846153846154,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.916,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.365,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.326,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.155,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.955,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.889,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.682,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.709,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.828,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >